Jing Wang

Jing Wang

Auto-generated profile, based on publicly available information

Jing Wang

Science for Life Laboratory, Department of Biomedical and Clinical Sciences (BKV), Linköping University, Linköping, Sweden

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2022 in International Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
FCFei Chen
Fei Chen
YPYing Pan
Ying Pan
ZLZiqing Liu
Ziqing Liu
RHRong Huang
Rong Huang
JWJing Wang
Jing Wang
KZKaixin Zhou
Kaixin Zhou
Background. The aging population is increasingly susceptible to cardiovascular disease (CVD). Visit-to-visit variability in glucose and lipid levels both contributed to CVD risk independent of their mean values. However, whether variability in the triglyceride-glucose (TyG) index is a risk factor for CVD remains unknown. Research Design and Methods. In this retrospective study of electronic health records, 27,520 participants aged over 60 years were enrolled. The visit-to-visit variability of TyG index was calculated from annual health examination data and defined as average real variability (ARV), standard deviation (SD), or the coefficient of variability (CV). CVD events were identified from the chronic disease registry or follow-up database and included myocardial infarction, angina, coronary, and stroke. Multivariate Cox regression was used to examine the correlation between TyG variability and incident CVD. Results. Over a median follow-up of 6.2 years, there were 2,178 CVD events. When participants were divided into four quartiles according to their TyG variability, after adjusting for established CVD risk factors, subjects in the top quartile had (HR = 1.18, 95% CI 1.05–1.34, ) significantly higher CVD risk than those in the bottom quartile. The association remained significant in overweight individuals or those without diabetes ( and , respectively). Conclusions. High variability in TyG was significantly associated with elevated CVD risk in the elderly, independent of average TyG and other risk factors. Close monitoring variability in TyG might be informative to identify old individuals at high risk of CVD.

17 August 2011 in International Journal of Urology
Verified
Journal Article
Closed access
PDF file
CCCaixia Cao
Caixia Cao
XYXuecheng Yang
Xuecheng Yang
Li LiLi Li
Li Li
RSRuixia Sun
Ruixia Sun
YXYuxin Xian
Yuxin Xian
YGYanyan Gao
Yanyan Gao

1 January 2006 in Applied Bioinformatics
Verified
Journal Article
Closed access
PDF file
YJYuan Ji
Yuan Ji
KCKevin R. Coombes
Kevin R. Coombes
JZJiexin Zhang
Jiexin Zhang
Sijin WenSijin Wen
Sijin Wen
JMJames Mitchell
James Mitchell
JWJing Wang
Jing Wang

20 March 2023 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
JWJing Wang
Jing Wang
HLHua Liang
Hua Liang
YWYou Wang
You Wang
XZXueying Zheng
Xueying Zheng
FCFei Chen
Fei Chen
KZKaixin Zhou
Kaixin Zhou
Metformin is the first-line drug for type 2 diabetes (T2D) while acarbose is suggested as a viable alternative in Chinese patients with newly diagnosed T2D. However, few biomarkers have been established to guide the choice between these two agents. Mitochondrial DNA (mtDNA) copy number (mtDNA-CN) is a biomarker of mitochondrial function, which is associated with various metabolic outcomes. Using data from the trial of Metformin and Acarbose in Chinese as the Initial Hypoglycaemic Treatment (MARCH) (metformin n = 214; acarbose n = 198), we examined whether mtDNA-CN was associated with response to the drugs in terms of glycemic response and b-cell function protection response. The glycemic response is defined as the maximum glucose reduction of glycated hemoglobin A(1c), fasting plasma glucose, or postprandial blood glucose during 48 weeks. b-cell function protection response is defined as the maximum increment of insulinogenic index (IGI) or disposition index (DI). For all three glycemic responses, mtDNA-CN was not significantly associated with either metformin or acarbose. Importantly, for b-cell function protection response, we found the increased mtDNA-CN was significantly associated with more IGI increment (beta: 0.84; 95% confidence interval (CI), 0.02 to 1.66) in the metformin group, but less IGI increment (beta: -1.38; 95% CI, -2.52 to -0.23) in the acarbose group. A significant interaction (P = 0.008) between mtDNA-CN and the treatment group was observed. Consistent results were also obtained when DI increment was used as a measure of b-cell function response. This study demonstrated the potential application of mtDNA-CN in guiding the treatment choice between metformin and acarbose based on b-cell protection.

24 September 2024 in medRxiv
Verified
Preprint
Open access
PDF file
JWJing Wang
Jing Wang
AZAlberto Zenere
Alberto Zenere
XWXingyue Wang
Xingyue Wang
GBGöran Bergström
Göran Bergström
FEFredrik Edfors
Fredrik Edfors
WZWen Zhong
Wen Zhong
Background: Understanding how genetics and environmental factors shape human metabolic profiles is crucial for advancing metabolic health. Variability in metabolic profiles, influenced by genetic makeup, lifestyle, and environmental exposures, plays a critical role in disease susceptibility and progression. Methods: We conducted a two-year longitudinal study involving 101 clinically healthy individuals aged 50 to 65, integrating genomics, metabolomics, lipidomics, proteomics, clinical measurements, and lifestyle questionnaire data from repeat sampling. We evaluated the influence of both external and internal factors, including genetic predispositions, lifestyle factors, and physiological conditions, on individual metabolic profiles. Additionally, we developed an integrative metabolite-protein network to analyze protein-metabolite associations under both genetic and environmental regulations. Results: Our findings highlighted the significant role of genetics in determining metabolic variability, identifying 22 plasma metabolites as genetically predetermined. Environmental factors such as seasonal variation, weight management, smoking, and stress also significantly influenced metabolite levels. The integrative metabolite-protein network comprised 5,649 significant protein-metabolite pairs and identified 87 causal metabolite-protein associations under genetic regulation, validated by showing a high replication rate in an independent cohort. This network revealed stable and unique protein-metabolite profiles for each individual, emphasizing metabolic individuality. Notably, our results demonstrated the importance of plasma proteins in capturing individualized metabolic variabilities. Key proteins representing individual metabolic profiles were identified and validated in the UK Biobank, showing great potential for predicting metabolic diseases and metabolic risk assessment. Conclusions: Our study provides longitudinal insights into how genetic and environmental factors shape human metabolic profiles, revealing unique and stable individual metabolic profiles. Plasma proteins emerged as key indicators for capturing the variability in human metabolism and assessing metabolic risks. These findings offer valuable tools for personalized medicine and the development of diagnostics for metabolic diseases.

3 April 2023
Verified
Other
Open access
JWJing Wang
Jing Wang
NPNatalie W. Pursell
Natalie W. Pursell
MSMaria Elena S. Samson
Maria Elena S. Samson
RARuzanna Atoyan
Ruzanna Atoyan
AMAnna W. Ma
Anna W. Ma
CLCheng-Jung Lai
Cheng-Jung Lai
PDF file - 178K, Changes in live cell numbers induced by the treatment of CUDC-101, erlotinib, or vorinostat in conditions used in the migration and invasion assays.